Farr M, Bacon P A, Coppock J, Scott D L
Department of Rheumatology, University of Birmingham, UK.
Scand J Rheumatol Suppl. 1987;64:37-47. doi: 10.3109/03009748709096720.
Our studies have shown that Salazopyrin EN is an effective slow-acting anti-rheumatic drug, improving clinical synovitis, depressing the acute phase response, capable of inducing remissions and possibly influencing the progression of joint damage. It is well-tolerated in the long-term with comparatively few serious side effects. Its mechanism of action, however, is still not entirely clear. We have found that the sulphapyridine moiety penetrates the synovial membrane and also that it can modify immune function. While Salazopyrin undoubtedly has an important role in the therapy of rheumatoid arthritis, it probably also has a place in the treatment of seronegative arthropathies and the spondyloarthritides. Furthermore we suggest that it should be used as an anchor drug in combination therapy to attempt to suppress disease activity further and limit joint damage.
我们的研究表明，柳氮磺胺吡啶肠溶片是一种有效的慢作用抗风湿药物，可改善临床滑膜炎，抑制急性期反应，能够诱导病情缓解，并可能影响关节损伤的进展。长期使用耐受性良好，严重副作用相对较少。然而，其作用机制仍不完全清楚。我们发现，磺胺吡啶部分可穿透滑膜，并且还能改变免疫功能。虽然柳氮磺胺吡啶无疑在类风湿关节炎的治疗中具有重要作用，但它可能在血清阴性关节病和脊柱关节炎的治疗中也占有一席之地。此外，我们建议将其用作联合治疗中的基础药物，以进一步抑制疾病活动并限制关节损伤。
